Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently

Zhang, Shaoting ; Zhang, Liangying ; Jiang, Zongying ; Guo, Yue ; Zhao, Hui and Sun, Jianmin LU (2021) In Biochemistry and Biophysics Reports 26.
Abstract

Activation of receptor tyrosine kinases needs tight control by tyrosine phosphatases to keep their normal function. In this study, we investigated the regulation of activation of the type III receptor tyrosine kinase KIT by protein tyrosine phosphatase receptor type E (PTPRE). We found that PTPRE can associate with wild-type KIT and inhibit KIT activation in a dose-dependent manner, although the activation of wild-type KIT is dramatically inhibited even when PTPRE is expressed at low level. The D816V mutation of KIT is the most frequently found oncogenic mutation in mastocytosis, and we found that PTPRE can associate and inhibit the activation of KIT/D816V in a dose dependent manner, but the inhibition is much weaker compared with... (More)

Activation of receptor tyrosine kinases needs tight control by tyrosine phosphatases to keep their normal function. In this study, we investigated the regulation of activation of the type III receptor tyrosine kinase KIT by protein tyrosine phosphatase receptor type E (PTPRE). We found that PTPRE can associate with wild-type KIT and inhibit KIT activation in a dose-dependent manner, although the activation of wild-type KIT is dramatically inhibited even when PTPRE is expressed at low level. The D816V mutation of KIT is the most frequently found oncogenic mutation in mastocytosis, and we found that PTPRE can associate and inhibit the activation of KIT/D816V in a dose dependent manner, but the inhibition is much weaker compared with wild-type KIT. Similar to mastocytosis, KIT mutations are the main oncogenic mutations in gastrointestinal stromal tumors (GISTs) although GISTs carry different types of KIT mutations. We further studied the regulation of the activation of GISTs-type KIT mutants and other mastocytosis-type KIT mutants by PTPRE. Indeed, PTPRE can almost block the activation of GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to the inhibition of PTPRE. Taken together, our results suggest that PTPRE can associate with KIT, and inhibit the activation of both wild-type KIT and GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to PTPRE.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
GISTs, KIT, Mastocytosis, Mutation, PTPRE
in
Biochemistry and Biophysics Reports
volume
26
article number
100974
publisher
Elsevier
external identifiers
  • scopus:85101775845
  • pmid:33732906
ISSN
2405-5808
DOI
10.1016/j.bbrep.2021.100974
language
English
LU publication?
yes
id
42571e06-87e5-41b3-bc8a-285bd1868529
date added to LUP
2021-12-22 10:56:39
date last changed
2024-07-28 03:28:55
@article{42571e06-87e5-41b3-bc8a-285bd1868529,
  abstract     = {{<p>Activation of receptor tyrosine kinases needs tight control by tyrosine phosphatases to keep their normal function. In this study, we investigated the regulation of activation of the type III receptor tyrosine kinase KIT by protein tyrosine phosphatase receptor type E (PTPRE). We found that PTPRE can associate with wild-type KIT and inhibit KIT activation in a dose-dependent manner, although the activation of wild-type KIT is dramatically inhibited even when PTPRE is expressed at low level. The D816V mutation of KIT is the most frequently found oncogenic mutation in mastocytosis, and we found that PTPRE can associate and inhibit the activation of KIT/D816V in a dose dependent manner, but the inhibition is much weaker compared with wild-type KIT. Similar to mastocytosis, KIT mutations are the main oncogenic mutations in gastrointestinal stromal tumors (GISTs) although GISTs carry different types of KIT mutations. We further studied the regulation of the activation of GISTs-type KIT mutants and other mastocytosis-type KIT mutants by PTPRE. Indeed, PTPRE can almost block the activation of GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to the inhibition of PTPRE. Taken together, our results suggest that PTPRE can associate with KIT, and inhibit the activation of both wild-type KIT and GISTs-type KIT mutants, while the activation of mastocytosis-type KIT mutants is more resistant to PTPRE.</p>}},
  author       = {{Zhang, Shaoting and Zhang, Liangying and Jiang, Zongying and Guo, Yue and Zhao, Hui and Sun, Jianmin}},
  issn         = {{2405-5808}},
  keywords     = {{GISTs; KIT; Mastocytosis; Mutation; PTPRE}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Biochemistry and Biophysics Reports}},
  title        = {{Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently}},
  url          = {{http://dx.doi.org/10.1016/j.bbrep.2021.100974}},
  doi          = {{10.1016/j.bbrep.2021.100974}},
  volume       = {{26}},
  year         = {{2021}},
}